PDS Biotechnology logo

PDSB - PDS Biotechnology News Story

$5.52 -0.2  -3.0%

Last Trade - 9:00pm

Sector
Healthcare
Size
Small Cap
Market Cap £120.0m
Enterprise Value £68.3m
Revenue £n/a
Position in Universe 4970th / 7414

PDS Biotechnology Corp reports results for the quarter ended in September - Earnings Summary

Wed 10th November, 2021 2:32pm
* PDS Biotechnology Corp  PDSB.OQ  reported a quarterly adjusted
loss of 24 cents​​ per share for the quarter ended in September.
The mean expectation of seven analysts for the quarter was for a
loss of 20 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* PDS Biotechnology Corp's reported EPS for the quarter was a
loss of 24 cents​.
* The mean earnings estimate of analysts had fallen by
about 20.6% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* PDS Biotechnology Corp shares had fallen by 28.4% this
quarter and gained 398.6% so far this year.
* The company reported a quarterly loss of $6.96 million.
* Wall Street's median 12-month price target for PDS
Biotechnology Corp is $18.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 10 at 02:32 p.m.
 ​All figures in US dollars unless otherwise stated
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.